苦碟子注射液联合丁苯酞对急性脑梗死患者的临床研究

Clinical trial of Kudiezi injection combined with butylbenzene peptide in the treatment of patients with acute cerebral infarction

目的观察苦碟子注射液联合丁苯酞对急性脑梗死(ACI)患者的血清学及脑血流动力学的影响。方法将180例ACI患者随机分为对照组90例和试验组90例。对照组给予丁苯酞每次100 mL,每天2次,静脉滴注;试验组在对照组的基础上,给予苦碟子注射液40 mL,每天1次,静脉滴注。2组患者均治疗14 d。比较2组患者的临床疗效、美国国立卫生院神经功能量表(NIHSS)评分、日常生活能力量表(ADL)评分、血清学指标及脑血流指标。结果治疗后,试验组和对照组的总有效率分别为95.56%,82.22%,差异有统计学意义(P<0.05)。治疗后,试验组NIHSS,超敏C反应蛋白,白细胞介素(IL)-6,IL-8,脑血管周围阻力水平及血小板聚集率,ADL评分,平均血流量,平均血流速度分别为(6.23±0.35)分,(4.32±1.63)pg·mL^-1,(3.35±1.27)pg·mL^-1,(23.00±2.98)pg·mL^-1,(71.08±9.45)kPa·s·m^-1,(35.28±7.04)%,(68.98±2.19)分,(9.22±1.87)mL·s^-1,(18.76±5.36)cm·s^-1,对照组分别为(7.44±0.42)分,(5.56±1.88)pg·mL^-1,(4.98±2.31)pg·mL^-1,(26.87±3.23)pg·mL^-1,(85.30±7.74)kPa·s·m^-1,(45.39±8.29)%,(65.34±3.46)分,(7.83±1.93)mL·s^-1,(15.21±3.33)cm·s^-1,差异均有统计学意义(均P<0.05)。治疗期间,试验组和对照组的药物不良反应发生率分别为7.78%和12.22%,差异无统计学意义(P>0.05)。结论苦碟子注射液联合丁苯酞对ACI患者具有良好的临床疗效,可以显著改善其血清学及脑血流动力学指标,促进神经功能以及日常生活能力的提高。

Objective To investigate the effects of Kudiezi injection combined with butylbenzene peptide on serology and cerebral hemodynamics in patients with acute cerebral infarction(ACI).Methods A total of 180 patients with ACI were randomly divided into control group(90 cases)and treatment group(90 cases).Control group was treated with butylbenzene peptide 100 mL per time,twice a day,intravenous drip.Treatment group was given Kudiezi injection 40 mL,qd,intravenous drip,on the basis of control group.Both groups were treated for 14 d.The clinical efficacy,score of National Institutes of Health Stroke scale(NIHSS)and activity of daily living scale(ADL),serological index and cerebral hemodynamics index in two groups were compared.Results After treatment,the total effective rates in treatment group and control group were 95.56%and 82.22%,with significant difference(P<0.05).After treatment,the score of NIHSS,levels of high-sensitivity C-reaetive protein,interleukin(IL)-6,IL-8,peripheral cerebral vascular resistance,platelet aggregation rate and ADL,mean blood flow and mean blood velocity in treatment group were(6.23±0.35),(4.32±1.63)pg·mL^-1,(3.35±1.27)pg·mL^-1,(23.00±2.98)pg·mL^-1,(71.08±9.45)kpa·s·m^-1,(35.28±7.04)%,(68.98±2.19),(9.22±1.87)mL·s^-1,(18.76±5.36)cm·s^-1,all had significant difference with those in control group,which were(7.44±0.42)points,(5.56±1.88)pg·mL^-1,(4.98±2.31)pg·mL^-1,(26.87±3.23)pg·mL^-1,(85.30±7.74)kpa·s·m^-1,(45.39±8.29)%,(65.34±3.46),(7.83±1.93)mL·s^-1,(15.21±3.33)cm·s^-1(all P<0.05).During the treatment,the incidences of adverse drug reactions in treatment group and control group were 7.78%,12.22%,with no significant difference(P>0.05).Conclusion Kudiezi injection combined with butylbenzene peptide has a good clinical effect on patients with ACI,which can significantly improve the serological and cerebral hemodynamic indexes,promote the improvement of nerve function and daily living ability.